Lifecore Biomedical Inc（LFCR）财务数据LFCRLifecore Biomedical Inc

Lifecore Biomedical, Inc. (LFCR) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is HA manufacturing, accounting for 54.5% of total sales, equivalent to $18.61M. Another important revenue stream is CDMO. Understanding this composition is critical for investors evaluating how LFCR navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Lifecore Biomedical, Inc. maintains a gross margin of 26.96%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -3.53%, while the net margin is -158.30%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively LFCR converts its operational activities into shareholder value.

In the context of the broader market, LFCR competes directly with industry leaders such as IMRX and EVMN. With a market capitalization of $244.14M, it holds a leading position in the sector. When comparing efficiency, LFCR's gross margin of 26.96% stands against IMRX's N/A and EVMN's N/A. Such benchmarking helps identify whether Lifecore Biomedical, Inc. is trading at a premium or discount relative to its financial performance.

Lifecore's revenue for Q2 2026 was $34.2 million, but it reported a net loss of -$7.1 million. The gross margin improved to 35.34%, which is a positive sign, but the overall financial health is concerning due to consistent losses.